Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...